Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases-Reference-Cited by-同舟云学术

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases

Published:2023-04-19 Issue:4 Volume:13 Page:688
ISSN:2075-4426
Container-title:Journal of Personalized Medicine
language:en
Short-container-title:JPM

Author:

Manfredi Mariangela¹,Van Hoovels Lieve²³,Benucci Maurizio⁴,De Luca Riccardo⁵,Coccia Carmela⁵,Bernardini Pamela⁵,Russo Edda⁵^ORCID,Amedei Amedeo⁵^ORCID,Guiducci Serena⁵,Grossi Valentina¹,Bossuyt Xavier²⁶,Perricone Carlo⁷^ORCID,Infantino Maria¹^ORCID

Affiliation:

1. Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, 50143 Florence, Italy

2. Department of Microbiology, Immunology and Transplantation, University of Leuven, 3000 Leuven, Belgium

3. Department of Laboratory Medicine, OLV Hospital, 9300 Aalst, Belgium

4. Rheumatology Unit, S. Giovanni di Dio Hospital, 50143 Florence, Italy

5. Department of Clinical and Experimental Medicine, University of Florence, 50139 Florence, Italy

6. Department of Laboratory Medicine, University Hospital Leuven, 3000 Leuven, Belgium

7. Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, 06122 Perugia, Italy

Abstract

The soluble urokinase plasminogen activator receptor (suPAR) is the bioactive form of uPAR, a membrane-bound glycoprotein, and it is primarily expressed on the surface of immunologically active cells. Mirroring local inflammation and immune activation, suPAR has gained interest as a potential prognostic biomarker in several inflammatory diseases. Indeed, in many diseases, including cancer, diabetes, cardiovascular diseases, kidney diseases, and inflammatory disorders, higher suPAR concentrations have been associated with disease severity, disease relapse, and mortality. Our review describes and discusses the supporting literature concerning the promising role of suPAR as a biomarker in different autoimmune rheumatic and non-rheumatic diseases.

Publisher

MDPI AG

Subject

Medicine (miscellaneous)

Link

https://www.mdpi.com/2075-4426/13/4/688/pdf

Reference58 articles.

1. suPAR: The molecular crystal ball;Thuno;Dis. Markers,2009

2. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation;Rasmussen;Front. Immunol.,2021

3. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion;Ellis;Fibrinolysis,1994

4. The urokinase receptor;Fibrinolysis Proteol.,1998

5. Regulation of cell signalling by uPAR;Smith;Nat. Rev. Mol. Cell. Biol.,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in Adult Allogeneic Hematopoietic Cell Transplantation Recipients;International Journal of Molecular Sciences;2023-12-23